SmithKline Beecham switch candidates
This article was originally published in The Tan Sheet
Executive Summary
In addition to the H[2] antagonist cimeditine (Tagamet) and the smoking cessation aids Nicorette and Nicoderm from the 1992 joint venture with Marion Merrell Dow, SmithKline Beecham identifies the topical antibiotic Bactroban (mupirocin 2% ointment) as another Rx-to-OTC switch candidate in the company's 1993 annual report, In 1993, SmithKline Beecham's worldwide consumer health care business posted a 12% sales increase to nearly $2 bil., with trading profit increasing 9% to $245 mil. SmithKline's U.S. consumer health care sales of $684 mil. in 1993, which for the first time includes full-year sales from MMD's OTCs, accounted for 34% of the firm's worldwide consumer health care sales, up from 25% in 1992
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning